Current Report Filing (8-k)
15 November 2017 - 9:02AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of the earliest event reported): November 14, 2017 (November 14, 2017)
Valeant Pharmaceuticals International, Inc.
(Exact Name of Registrant as Specified in Its Charter)
|
|
|
|
|
British Columbia, Canada
|
|
001-14956
|
|
98-0448205
|
(State or Other Jurisdiction of
Incorporation or Organization)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification Number)
|
2150 St. Elzéar Blvd. West
Laval, Quebec
Canada H7L
4A8
(Address of Principal Executive Offices)(Zip Code)
514-744-6792
(Registrants telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Pricing of Secured Notes Offering
On November 14, 2017, Valeant Pharmaceuticals International, Inc. issued a press release announcing that, on November 14, 2017, it had priced its
offering of $750 million aggregate principal amount of 5.500% senior secured notes due 2025 (the notes). The notes will be additional notes and form part of the same series as the Companys existing 5.500% senior secured notes
due 2025.
A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Item 9.01
|
Financial Statements and Exhibits
|
(d) Exhibits
|
|
|
Exhibit
Number
|
|
Description
|
99.1
|
|
Press Release announcing the pricing of the secured notes offering, dated November 14,
2017.
|
2
EXHIBIT INDEX
3
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
|
|
|
By:
|
|
/s/ Paul S. Herendeen
|
|
|
Name:
|
|
Paul S. Herendeen
|
|
|
Title:
|
|
Executive Vice President and Chief Financial Officer
|
Date: November 14, 2017
4
Valeant Pharma (NYSE:VRX)
Historical Stock Chart
From Apr 2024 to May 2024
Valeant Pharma (NYSE:VRX)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Bausch Health Cos (New York Stock Exchange): 0 recent articles
More Valeant Pharmaceuticals International, Inc. News Articles